NeurAxis (NASDAQ:NRXS – Get Free Report) is one of 75 public companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare NeurAxis to related companies based on the strength of its valuation, profitability, earnings, risk, institutional ownership, analyst recommendations and dividends.
Profitability
This table compares NeurAxis and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NeurAxis | -594.55% | N/A | -899.27% |
NeurAxis Competitors | -322.79% | -38.95% | -22.42% |
Valuation & Earnings
This table compares NeurAxis and its peers top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
NeurAxis | $2.46 million | -$14.63 million | -0.71 |
NeurAxis Competitors | $985.67 million | $86.01 million | 7.36 |
Analyst Ratings
This is a breakdown of current recommendations for NeurAxis and its peers, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
NeurAxis Competitors | 231 | 750 | 2000 | 98 | 2.64 |
As a group, “Electromedical equipment” companies have a potential upside of 33.48%. Given NeurAxis’ peers higher possible upside, analysts plainly believe NeurAxis has less favorable growth aspects than its peers.
Insider & Institutional Ownership
11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 45.8% of shares of all “Electromedical equipment” companies are owned by institutional investors. 15.0% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
NeurAxis peers beat NeurAxis on 9 of the 12 factors compared.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.